Literature DB >> 26873743

Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias.

Hironao Hozumi1,2, Noriyuki Enomoto3, Yoshiyuki Oyama3, Masato Kono3, Tomoyuki Fujisawa3, Naoki Inui4, Yutaro Nakamura3, Takafumi Suda3.   

Abstract

PURPOSE: The clinical significance of proteinase-3-antineutrophil cytoplasmic antibody (PR3-ANCA) positivity is not well established in idiopathic interstitial pneumonia (IIP) patients. We aimed to determine the clinical features of PR3-ANCA-positive IIP patients.
METHODS: We retrospectively reviewed 377 consecutive IIP patients; of these, 360 patients had PR3-ANCA and myeloperoxidase-antineutrophil cytoplasmic antibody test results available. The clinical features of PR3-ANCA-positive IIP patients and control ANCA-negative idiopathic pulmonary fibrosis patients (ANCA-negative IPF) were compared.
RESULTS: Sixteen patients (4.4 %) were PR3-ANCA-positive IIP and 94 (26 %) were ANCA-negative IPF. The median age at diagnosis (72 vs. 70 years, P = 0.17) and proportion of males (75 vs. 89 %, P = 0.12) in PR3-ANCA-positive IIP and ANCA-negative IPF patients, respectively, were not significantly different. Radiologically, the HRCT patterns of PR3-ANCA-positive IIP patients varied (UIP, n = 3, 18.8 %; possible UIP, n = 3, 18.8 %; NSIP, n = 5, 31.3 %; unclassifiable CT pattern, n = 5, 31.3 %) more than those of ANCA-negative IPF patients (UIP, n = 69, 73.4 %; possible UIP, n = 25, 26.6 %; P < 0.001). No PR3-ANCA-positive IIP patients developed ANCA-associated vasculitis. The 5-year survival rate was 50 % in PR3-ANCA-positive IIP patients and 52 % in ANCA-negative IPF patients with no significant difference (P = 0.96 by log-rank test).
CONCLUSIONS: The HRCT patterns of PR3-ANCA-positive IIP patients varied more than those of the IPF patients, but the clinical features of high IIP-onset age and male predominance were similar between the groups. Furthermore, PR3-ANCA-positive IIP patients had a poor prognosis similar to that of IPF patients.

Entities:  

Keywords:  ANCA; ILD; Interstitial lung disease; Interstitial pneumonia; PR3-ANCA; Proteinase-3-antineutrophil cytoplasmic antibody

Mesh:

Substances:

Year:  2016        PMID: 26873743     DOI: 10.1007/s00408-016-9851-x

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  29 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions.

Authors:  J H Stone; M Talor; J Stebbing; M L Uhlfelder; N R Rose; K A Carson; D B Hellmann; C L Burek
Journal:  Arthritis Care Res       Date:  2000-12

3.  Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis.

Authors:  Masaru Ando; Eishi Miyazaki; Toshihiro Ishii; Yutaka Mukai; Mari Yamasue; Hideaki Fujisaki; Takeo Ito; Shin-ichi Nureki; Toshihide Kumamoto
Journal:  Respir Med       Date:  2013-02-19       Impact factor: 3.415

4.  Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD).

Authors:  Takafumi Suda; Masato Kono; Yutaro Nakamura; Noriyuki Enomoto; Yusuke Kaida; Tomoyuki Fujisawa; Shiro Imokawa; Kazumasa Yasuda; Hideo Hashizume; Koushi Yokomura; Mikio Toyoshima; Naoki Koshimizu; Hideki Suganuma; Toshihiro Shirai; Dai Hashimoto; Naoki Inui; Thomas V Colby; Kingo Chida
Journal:  Respir Med       Date:  2010-05-18       Impact factor: 3.415

5.  Connective tissue disease-associated interstitial lung disease: a call for clarification.

Authors:  Aryeh Fischer; Sterling G West; Jeffrey J Swigris; Kevin K Brown; Roland M du Bois
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

6.  Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients.

Authors:  Tomonori Tanaka; Kyoko Otani; Ryoko Egashira; Yukio Kashima; Hiroyuki Taniguchi; Yasuhiro Kondoh; Kensuke Kataoka; Akira Shiraki; Yasuhiko Kitasato; Kevin O Leslie; Junya Fukuoka
Journal:  Respir Med       Date:  2012-09-17       Impact factor: 3.415

7.  A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients.

Authors:  Tomoko Nozu; Mitsuko Kondo; Kazuo Suzuki; Jun Tamaoki; Atsushi Nagai
Journal:  Respiration       Date:  2008-12-11       Impact factor: 3.580

8.  The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase.

Authors:  P B Gaudin; F B Askin; R J Falk; J C Jennette
Journal:  Am J Clin Pathol       Date:  1995-07       Impact factor: 2.493

9.  Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Sakae Homma; Hiroshi Matsushita; Koichiro Nakata
Journal:  Respirology       Date:  2004-06       Impact factor: 6.424

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  10 in total

Review 1.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

2.  Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Gabrielle Y Liu; Iazsmin Bauer Ventura; Natalia Achtar-Zadeh; Brett M Elicker; Kirk D Jones; Paul J Wolters; Harold R Collard; Ayodeji Adegunsoye; Mary E Strek; Brett Ley
Journal:  Chest       Date:  2019-06-07       Impact factor: 9.410

Review 3.  Interstitial Pneumonia with Autoimmune Features.

Authors:  Bridget A Graney; Aryeh Fischer
Journal:  Ann Am Thorac Soc       Date:  2019-05

4.  [Value of anti-neutrophil cytoplasmic antibody in assessing the severity of bronchiolitis obliterans in children].

Authors:  Xiao-Wen Chen; De-Hui Chen; Shang-Zhi Wu; Na Xie; Wen-Kuan Liu; Yu-Neng Lin; Ya-Wen Zhang; Qing-Si Zeng
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-09

5.  Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus.

Authors:  Fang Su; Weiguo Xiao; Pingting Yang; Qingyan Chen; Xiaojie Sun; Tienan Li
Journal:  An Bras Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.896

Review 6.  Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases.

Authors:  Helena Crisford; Elizabeth Sapey; Robert A Stockley
Journal:  Respir Res       Date:  2018-09-20

7.  Systematic review and meta-analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMJ Open       Date:  2019-05-29       Impact factor: 2.692

8.  Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody.

Authors:  Xin Sun; Min Peng; Ting Zhang; Zongru Li; Lan Song; Mengtao Li; Juhong Shi
Journal:  BMC Pulm Med       Date:  2021-03-16       Impact factor: 3.317

Review 9.  ANCA-associated vasculitis in idiopathic pulmonary fibrosis: A case report and brief review of the literature.

Authors:  Daniel Traila; Monica Steluta Marc; Camelia Pescaru; Diana Manolescu; Ovidiu Fira-Mladinescu
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

10.  Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients.

Authors:  Guillermo Suarez-Cuartin; Maria Molina-Molina
Journal:  Breathe (Sheff)       Date:  2020-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.